Expression of miR-126 and its potential function in coronary artery disease

Wang, Xiaoyan; Lian, Yajun; Wen, Xin; Guo, Jing; Wang, Zhiping; Jiang, Sheng Nan; Hu, Yaodong

doi:10.4314/ahs.v17i2.22

Cited by 47 publications

(34 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Placental miR-16 expression predicts the risk of being born SGA [26] and miR-16-5p is down-regulated in IUGR pregnancies [43]. MiR-126 expression is down-regulated in patients with coronary artery disease [44] and 5. (a and b).…”

Section: Discussionmentioning

confidence: 99%

A prospective case-control study on miRNA circulating levels in subjects born small for gestational age (SGA) evaluated from childhood into young adulthood

et al. 2020

View full text Add to dashboard Cite

Objective microRNAs (miRNAs) associated with metabolic risk have never been extensively investigated in SGA subjects. The aim of the current study was to evaluate miRNAs in SGA and AGA subjects and their relationships with the metabolic status and growth. Design and methodsA prospective longitudinal case-control study was performed in 23 SGA with postnatal catch-up growth and 27 AGA subjects evaluated at the age of 9 and 21 years. Circulating levels of miR-122-5p, miR-16-5p, miR-126-3p, and miR-486-5p were assessed by qPCR. OPEN ACCESSCitation: Inzaghi E, Kistner A, Germani D, Deodati A, Vanpee M, Legnevall L, et al. (2020) A prospective case-control study on miRNA circulating levels in subjects born small for gestational age (SGA) evaluated from childhood into young adulthood. PLoS ONE 15(1): e0228075.

show abstract

Section: Discussionmentioning

confidence: 99%

A prospective case-control study on miRNA circulating levels in subjects born small for gestational age (SGA) evaluated from childhood into young adulthood

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It was proved that this calcineurin/NFAT pathway is activated after oxidative stress stimuli [157,158]. In the in vivo experiments, inhibition of miRNA-199b caused normalization of the expression of Dyrk1a, a reduction of nuclear NFAT activity, and inhibition of hypertrophy and fibrosis in mouse models of heart failure [101,159]. Changed expressions of miRNA-1, -214, -29b, -342, -7, -107, -126, -125, -122, -423-5p, -320a, -650, -1228, -662, -583, -3175, -21, -22, and -92b have been shown in other studies of heart failure [106,152,156,[160][161][162][163].…”

Section: Heart Failurementioning

confidence: 99%

Oxidative Stress-Responsive MicroRNAs in Heart Injury

Kura

Bačová

Kaločayová

et al. 2020

IJMS

127

View full text Add to dashboard Cite

Reactive oxygen species (ROS) are important molecules in the living organisms as a part of many signaling pathways. However, if overproduced, they also play a significant role in the development of cardiovascular diseases, such as arrhythmia, cardiomyopathy, ischemia/reperfusion injury (e.g., myocardial infarction and heart transplantation), and heart failure. As a result of oxidative stress action, apoptosis, hypertrophy, and fibrosis may occur. MicroRNAs (miRNAs) represent important endogenous nucleotides that regulate many biological processes, including those involved in heart damage caused by oxidative stress. Oxidative stress can alter the expression level of many miRNAs. These changes in miRNA expression occur mainly via modulation of nuclear factor erythroid 2-related factor 2 (Nrf2), sirtuins, calcineurin/nuclear factor of activated T cell (NFAT), or nuclear factor kappa B (NF-κB) pathways. Up until now, several circulating miRNAs have been reported to be potential biomarkers of ROS-related cardiac diseases, including myocardial infarction, hypertrophy, ischemia/reperfusion, and heart failure, such as miRNA-499, miRNA-199, miRNA-21, miRNA-144, miRNA-208a, miRNA-34a, etc. On the other hand, a lot of studies are aimed at using miRNAs for therapeutic purposes. This review points to the need for studying the role of redox-sensitive miRNAs, to identify more effective biomarkers and develop better therapeutic targets for oxidative-stress-related heart diseases.

show abstract

“…Other studies have also reported that circulating miR-19a, miR-29a, miR-30e, miR-145, miR-150, miR-155, miR-181d, miR-342, miR-378 and miR-484 levels are decreased in patients with stable CAD [152] and has been associated with subclinical atherosclerosis [152]. CAD severity was found to be inversely associated with circulating miR-126 levels [153]. Studies in patients with acute myocardial infarction (AMI) have identified several miRNAs which have the potential to act as predictive biomarkers.…”

Section: Circulating Mirnas As Potential Clinical Biomarkers For Athementioning

confidence: 86%

MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis

Solly

Dimasi

Bursill

et al. 2019

JCM

View full text Add to dashboard Cite

Atherosclerotic cardiovascular disease remains the leading cause of morbidity and mortality worldwide. Atherosclerosis develops over several decades and is mediated by a complex interplay of cellular mechanisms that drive a chronic inflammatory milieu and cell-to-cell interactions between endothelial cells, smooth muscle cells and macrophages that promote plaque development and progression. While there has been significant therapeutic advancement, there remains a gap where novel therapeutic approaches can complement current therapies to provide a holistic approach for treating atherosclerosis to orchestrate the regulation of complex signalling networks across multiple cell types and different stages of disease progression. MicroRNAs (miRNAs) are emerging as important post-transcriptional regulators of a suite of molecular signalling pathways and pathophysiological cellular effects. Furthermore, circulating miRNAs have emerged as a new class of disease biomarkers to better inform clinical diagnosis and provide new avenues for personalised therapies. This review focusses on recent insights into the potential role of miRNAs both as therapeutic targets in the regulation of the most influential processes that govern atherosclerosis and as clinical biomarkers that may be reflective of disease severity, highlighting the potential theranostic (therapeutic and diagnostic) properties of miRNAs in the management of cardiovascular disease.

show abstract

Expression of miR-126 and its potential function in coronary artery disease

Cited by 47 publications

References 22 publications

A prospective case-control study on miRNA circulating levels in subjects born small for gestational age (SGA) evaluated from childhood into young adulthood

A prospective case-control study on miRNA circulating levels in subjects born small for gestational age (SGA) evaluated from childhood into young adulthood

Oxidative Stress-Responsive MicroRNAs in Heart Injury

MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis

Contact Info

Product

Resources

About